Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | Q9HBH1 | 4/20 | 0.41 | |
| ▸ | FDPS | P14324 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21548738 | 1.00 | CA1 (0.48) | CA1ALDH1A1PDFFDPSCA2 | |
| SCHEMBL8938931 | 0.93 | CA1 (0.57) | CA1ALDH1A1FDPSACE2 | |
| SCHEMBL6117872 | 0.91 | CA1 (0.55) | CA1FDPSACE2 | |
| SCHEMBL6117421 | 0.91 | CA1 (0.55) | CA1FDPSACE2 | |
| SCHEMBL23055054 | 0.88 | CA1 (0.43) | CA1ALDH1A1PDFACE2CHRNB2 | |
| SCHEMBL15314112 | 0.86 | CHRM1 (0.39) | CA1ALDH1A1FDPSACE2CHRNB2 | |
| SCHEMBL6116358 | 0.86 | CHRM1 (0.39) | CA1ALDH1A1FDPSACE2CHRNB2 | |
| SCHEMBL23055048 | 0.86 | CA1 (0.41) | CA1ACE2CHRNB2CHRNB4CHRNA4 | |
| SCHEMBL15314113 | 0.86 | CHRM1 (0.39) | CA1ALDH1A1FDPSACE2CHRNB2 | |
| Hydrochloric Acid SCHEMBL6502387 | 0.84 | CHRM1 (0.37) | CA1ALDH1A1PDFFDPSMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092122-A1 | ADDITIVES IN RUBBER FORMULATIONS | BASF SE (DE) | 2024-03-21 | — | — | US | disclosed |
| CN-116685475-A | Additives in rubber formulations | 巴斯夫欧洲公司 | 2023-09-01 | — | — | CN | disclosed |
| US-10668033-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2020-06-02 | — | — | US | disclosed |
| US-20170360730-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| EP-1864977-B1 | NOVEL CYCLIC COMPOUND HAVING PYRIMIDINYLALKYLTHIO GROUP | SANTEN PHARMACEUTICAL CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| EP-2460802-B1 | TRIFLUOROMETHYLTHIOPHENIUM DERIVATIVE SALTS, PROCESS FOR PRODUCTION THEREOF, AND PROCESS FOR PRODUCTION OF TRIFLUOROMETHYL-CONTAINING COMPOUNDS USING SAME | NAGOYA INST TECHNOLOGY (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8703969-B2 | Trifluoromethylthiophenium derivative salt, method for producing the same, and method for producing trifluoromethyl-containing compounds using the same | NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2014-04-22 | — | — | US | disclosed |
| EP-2460802-A1 | TRIFLUOROMETHYLTHIOPHENIUM DERIVATIVE SALTS, PROCESS FOR PRODUCITON THEREOF, AND PROCESS FOR PRODUCTION OF TRIFLUOROMETHYL-CONTAINING COMPOUNDS USING SAME | Nagoya Institute of Technology (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120130090-A1 | TRIFLUOROMETHYLTHIOPHENIUM DERIVATIVE SALT, METHOD FOR PRODUCING THE SAME, AND METHOD FOR PRODUCING TRIFLUOROMETHYL-CONTAINING COMPOUNDS USING THE SAME | TOSOH F-TECH, INC. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170360730-A1 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | PTGIR, PTGIS, TBXA2R | CA1 4188/4885ALDH1A1 2567/4885PDF 1403/4885 |
| US-10668033-B2 | Modulators of the prostacyclin (PGI2) receptor useful for the treatment of disorders related thereto | PTGIR, PTGIS, TBXA2R | CA1 4188/4885ALDH1A1 2567/4885PDF 1403/4885 |
| US-20120130090-A1 | TRIFLUOROMETHYLTHIOPHENIUM DERIVATIVE SALT, METHOD FOR PRODUCING THE SAME, AND METHOD FOR PRODUCING TRIFLUOROMETHYL-CONTAINING COMPOUNDS USING THE SAME | TST, CBR3, CYP4B1 | CA1 2555/4885ALDH1A1 3183/4885PDF 4466/4885 |
| US-20080293701-A1 | 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors | REN, AGTR1, AGTR2 | CA1 4805/4885ALDH1A1 173/4885PDF 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.